Literature DB >> 23643295

FcγRI is required for TGFβ2-treated macrophage-induced tolerance.

Z Gu1, A Y Chhabra, P Alard, D R Warner, M M Kosiewicz.   

Abstract

Macrophages treated with TGFβ2 (TGFβ2-Mϕ) and antigen are highly tolerogenic in vivo, and induce antigen-specific and long-lasting tolerance in both naïve and primed mice via induction of suppressor/regulatory T cells. In this study, we examined the molecular pathways, including the requirements for Smad-dependent signaling, that are involved in the induction and function of tolerogenic TGFβ2-Mϕ. Treatment of murine macrophages with TGFβ2 induced translocation of Smad2/3 to the nucleus, and impairment of Smad3-, but not Smad2-, dependent signaling inhibited the tolerogenic function of a TGFβ2-treated murine macrophage cell line. Gene expression in murine macrophages treated with TGFβ2 was evaluated by microarray analysis. The FcγRI gene was one of a number of immune-related genes differentially expressed in TGFβ2-Mϕ, and appeared to be critical for tolerance in this system, since TGFβ2-Mϕ from FcγRI deficient mice were unable to induce tolerance. The role that FcγRI plays in TGFβ2-Mϕ-mediated tolerance is currently unclear. The results of this study provide important information about the factors that are critical for the induction of TGFβ2-Mϕ-mediated tolerance, and a better understanding of these mechanisms could lead to the development of more effective tolerance-inducing strategies for the treatment of autoimmune/inflammatory diseases.
Copyright © 2013 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  ACAID; ANOVA; APC; Antigen presenting cells; CFA; DN; DTH; Delayed type hypersensitivity; FcγR; LPS; Macrophages; Mice; Mϕ; Mϕ59; OVA; PEC; TGFβ; Tolerance; WT; analysis of variance; anterior chamber-associated immune deviation; antigen presenting cells; complete Freund's adjuvant; delayed type hypersensitivity; dominant negative; i.v.; intravenous; lipopolysaccharide; macrophage; macrophage hybridoma cell line; ovalbumin; peritoneal exudates cells; s.c.; subcutaneous; transforming growth factor β; wild-type

Mesh:

Substances:

Year:  2013        PMID: 23643295      PMCID: PMC3936576          DOI: 10.1016/j.imbio.2013.04.003

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  31 in total

1.  Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1.

Authors:  T J D'Orazio; E Mayhew; J Y Niederkorn
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

2.  Identification of three novel Smad binding proteins involved in cell polarity.

Authors:  Dennis R Warner; M Michele Pisano; Emily A Roberts; Robert M Greene
Journal:  FEBS Lett       Date:  2003-03-27       Impact factor: 4.124

3.  Mechanisms of tolerance induced by TGF beta-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGF beta.

Authors:  Pascale Alard; Sherry L Clark; Michele M Kosiewicz
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

4.  FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection.

Authors:  A Ioan-Facsinay; S J de Kimpe; S M M Hellwig; P L van Lent; F M A Hofhuis; H H van Ojik; C Sedlik; S A da Silveira; J Gerber; Y F de Jong; R Roozendaal; L A Aarden; W B van den Berg; T Saito; D Mosser; S Amigorena; S Izui; G J B van Ommen; M van Vugt; J G J van de Winkel; J S Verbeek
Journal:  Immunity       Date:  2002-03       Impact factor: 31.745

5.  Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.

Authors:  J W Streilein; J Y Niederkorn
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

6.  Role of splenic B cells in the immune privilege of the anterior chamber of the eye.

Authors:  J Y Niederkorn; E Mayhew
Journal:  Eur J Immunol       Date:  1995-10       Impact factor: 5.532

7.  Expression of thrombospondin in TGFbeta-treated APCs and its relevance to their immune deviation-promoting properties.

Authors:  Sharmila Masli; Bruce Turpie; Karl H Hecker; J Wayne Streilein
Journal:  J Immunol       Date:  2002-03-01       Impact factor: 5.422

8.  Identification of novel Smad binding proteins.

Authors:  Dennis R Warner; Emily A Roberts; Robert M Greene; M Michele Pisano
Journal:  Biochem Biophys Res Commun       Date:  2003-12-26       Impact factor: 3.575

Review 9.  Tolerogenic antigen-presenting cells: regulation of the immune response by TGF-beta-treated antigen-presenting cells.

Authors:  Michele M Kosiewicz; Pascale Alard
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

10.  Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.

Authors:  Michele M Kosiewicz; Pascale Alard; Shuang Liang; Sherry L Clark
Journal:  Int Immunol       Date:  2004-03-29       Impact factor: 4.823

View more
  2 in total

Review 1.  Macrophages and Uveitis in Experimental Animal Models.

Authors:  Salvador Mérida; Elena Palacios; Amparo Navea; Francisco Bosch-Morell
Journal:  Mediators Inflamm       Date:  2015-05-20       Impact factor: 4.711

2.  The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions.

Authors:  Tong Zhang; Xiaomin Song; Lanlan Xu; Jie Ma; Yanjuan Zhang; Wenfeng Gong; Yilu Zhang; Xiaosui Zhou; Zuobai Wang; Yali Wang; Yingdi Shi; Huichen Bai; Ning Liu; Xiaolong Yang; Xinxin Cui; Yanping Cao; Qi Liu; Jing Song; Yucheng Li; Zhiyu Tang; Mingming Guo; Lai Wang; Kang Li
Journal:  Cancer Immunol Immunother       Date:  2018-04-23       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.